Publications

Timothy T. Ferng, Samantha M. Pintar, Vanessa E. Kennedy, Shaheen Kabir, Theodore C. Tarver, Veronica Steri, Paul Phojanakong, Juwita Hübner, Carolina E. Morales, Jose M. Rivera, Aaron C. Logan, Benjamin Braun, Elliot Stieglitz, Luke A. Gilbert, Catherine C. Smith. CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition. Blood. 2024. PMID:

Bogdan Popescu, Madison Piao, Sydney Abelson, Carolina E. Morales, Khadija Yousuf, Jose M. Rivera, Cheryl A C Peretz, Elliot Stieglitz, Catherine C. Smith. Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations. Blood. 2024. PMID:

Michelle Wang, Krishna V. Komanduri, Debajyoti Datta, Ayan Patel, Barbee Whitaker, Artur Belov, Benjamin Rubin, Rohit Vashisht, Rosa Rodriguez-Monguio, Pelin Cinar, Steven Anderson, Atul Butte. AI Predicts Early Relapse Post-Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma Patients in a Multi-Center Real-World Study. Blood. 2024. PMID:

Jun Ma, Michael P Randall, Ming Lu, Lingjing Chen, Huimin Geng, Aishwarya Kumar, Saloni Malla, Mark Noviski, Ryan Rountree, James L. Rubenstein. BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models. Blood. 2024. PMID:

Michael P Randall, Huimin Geng, Lingjing Chen, Aishwarya Ballapuram, Chitoh Yung, Ming Lu, Gregory Chin, Michael Mish, Jamie Bates, James L. Rubenstein. Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma. Blood. 2024. PMID:

Alvaro J Alencar, Olivia Bobek, Neha Mehta-Shah, Narendranath Epperla, Christine Lu-Emerson, Sarah C. Rutherford, Adam J. Olszewski, Thomas Ollila, Samuel Singer, Travis Dockter, Susan M. Geyer, Lori Rosenstein, Macarena De La Fuente, Eric D. Hsi, Shira N. Dinner, James L. Rubenstein, Nancy L. Bartlett, John P. Leonard. Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). Blood. 2024. PMID:

Mei R, Pepe E, Oh DY, Tsai KK, Chugh R, Kattah MG. Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab. Inflammatory bowel diseases. 2024. PMID: 39495057

Gonzalez-Martinez D, Roth L, Mumford TR, Guan J, Le A, Doebele RC, Huang B, Tulpule A, Niewiadomska-Bugaj M, Bivona TG, Bugaj LJ. Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance. Nature communications. 2024. PMID: 39488530

Kwon DH, Trihy L, Darvish N, Hearst E, Sumra S, Borno HT, Bose R, Chou J, de Kouchkovsky I, Desai A, Ekstrand B, Friedlander T, Kaur G, Koshkin VS, Nesheiwat S, Sepucha K, Small EJ, Aggarwal RR, Belkora J. Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer medicine. 2024. PMID: 39569542

Nanivadekar AC, Bose R, Petersen BA, Okorokova EV, Sarma D, Madonna TJ, Barra B, Farooqui J, Dalrymple AN, Levy I, Helm ER, Miele VJ, Boninger ML, Capogrosso M, Bensmaia SJ, Weber DJ, Fisher LE. Publisher Correction: Restoration of sensory feedback from the foot and reduction of phantom limb pain via closed-loop spinal cord stimulation. Nature biomedical engineering. 2024. PMID: 38155296

Aggarwal R, Blankstein R, Bhatt DL. The PRECISE trial: How should patients with chest pain be tested? Cleveland Clinic journal of medicine. 2024. PMID: 39486849

Weinfurtner K, Tischfield D, McClung G, Crainic J, Gordan J, Jiao J, Furth EE, Li W, Tuzneen Supan E, Nadolski GJ, Hunt SJ, Kaplan DE, Gade TPF. Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts. bioRxiv : the preprint server for biology. 2024. PMID: 39554038

Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E. Metastatic insulinoma-outcomes in the current era. The oncologist. 2024. PMID: 39475415

Siefker-Radtke AO, Huddart RA, Bilen MA, Balar A, Castellano D, Sridhar SS, De Giorgi U, Penkov K, Vasiliev A, Peer A, Järvinen R, Harputluoglu H, Koshkin VS, Poushnejad S, Wang T, Qureshi A, Tagliaferri MA, Zalevsky J, Loriot Y. Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10). Urologic oncology. 2024. PMID: 39477771

Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer LJV', Esserman L, Rugo HS. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. PMID: 39477071

Shamamian PE, Kwon DY, Oleru O, Seyidova N, Suydam R, Wang C, Montalmant K, Horesh E, Taub PJ. Assessing racial disparities in gender-affirming surgery utilization and hospital-level experience. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2024. PMID: 39541708

Cote GM, Kochupurakkal BS, Do K, Bullock A, Cheng ML, Muzikansky A, McLoughlin DE, Cleary JM, Gao X, Parikh A, Park JC, Weekes CD, Yeku O, Zou L, Shapiro GI. A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 39453756

Lai JC, Ring M, Dhruva A, Yeh GY. A patient-centered approach to dietary supplements for patients with chronic liver disease. Hepatology communications. 2024. PMID: 39445862

Kassaye I, Alyafaie A, Zhang K, Lifton J, Gordan JD, Kelley RK, Yung M. Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma. JAMA ophthalmology. 2024. PMID: 39446357

Wen RM, Stark JC, Marti GEW, Fan Z, Lyu A, Garcia Marques FJ, Zhang X, Riley NM, Totten SM, Bermudez A, Nolley R, Zhao H, Fong L, Engleman EG, Pitteri SJ, Bertozzi CR, Brooks JD. Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer. The Journal of clinical investigation. 2024. PMID: 39436703